[Skip to Navigation]
July 2017

Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug

Author Affiliations
  • 1Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
JAMA Ophthalmol. 2017;135(7):815-818. doi:10.1001/jamaophthalmol.2017.1810

Primary vitreoretinal lymphoma (PVRL) is a malignant large B-cell lymphoma affecting the eye and brain, with 5-year cumulative survival rate of 35% in those with brain involvement (68% in those without).1 Ocular involvement manifests with aggregated tumor cells in the vitreous, retina, optic disc, and subretinal pigment epithelial space. Management involves treatment of both eyes and brain, and treatment options for the eye(s) include systemic chemotherapy, external radiotherapy, or intravitreal injection of chemotherapy.

Add or change institution